$HYPR
Hyperfine, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022024488 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q3
Revenue $2.348M $1.533M $371.0K
YoY Change 532.88% 328.21%
Cost Of Revenue $1.660M $1.698M $709.0K
YoY Change 134.13% 271.55%
Gross Profit $688.0K -$165.0K -$338.0K
YoY Change -303.55% 66.67%
Gross Profit Margin 29.3% -10.76% -91.11%
Selling, General & Admin $6.632M $15.76M $9.614M
YoY Change -31.02% 86.53%
% of Gross Profit 963.95%
Research & Development $7.338M $7.265M $6.438M
YoY Change 13.98% 20.34%
% of Gross Profit 1066.57%
Depreciation & Amortization $238.0K $263.0K $172.0K
YoY Change 38.37% 115.57%
% of Gross Profit 34.59%
Operating Expenses $13.97M $23.03M $16.05M
YoY Change -12.97% 58.95%
Operating Profit -$13.28M -$23.19M -$900.4K
YoY Change 1375.09% 59.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$59.00K $1.000K $2.664K
YoY Change -2314.71% 0.0%
Pretax Income -$13.17M -$23.16M -$16.39M
YoY Change -19.65% 58.84%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.17M -$23.16M -$897.8K
YoY Change 1367.11% 58.84%
Net Earnings / Revenue -560.95% -1510.7% -241.98%
Basic Earnings Per Share -$0.19 -$0.33 -$8.66
Diluted Earnings Per Share -$0.19 -$0.33 -$8.66
COMMON SHARES
Basic Shares Outstanding 70.51M 70.35M 1.892M
Diluted Shares Outstanding 70.51M 70.35M 1.892M

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $132.5M $145.1M $525.4K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $4.002M $4.646M
Prepaid Expenses $402.2K
Receivables $2.702M $1.987M
Other Receivables
Total Short-Term Assets $143.7M $157.0M $927.6K
YoY Change 15393.33% 12571.87%
LONG-TERM ASSETS
Property, Plant & Equipment $3.448M $3.498M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.167M $1.179M
YoY Change
Total Long-Term Assets $4.615M $4.677M $207.0M
YoY Change -97.77% -97.74%
TOTAL ASSETS
Total Short-Term Assets $143.7M $157.0M $927.6K
Total Long-Term Assets $4.615M $4.677M $207.0M
Total Assets $148.3M $161.7M $207.9M
YoY Change -28.67% -22.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $741.0K $1.697M
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue $1.449M $964.0K
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.46M $10.46M $1.946M
YoY Change 540.1% 670.1%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.46M $10.46M $1.946M
Total Long-Term Liabilities
Total Liabilities $13.35M $11.20M $9.191M
YoY Change 45.22% 30.19%
SHAREHOLDERS EQUITY
Retained Earnings -$196.4M -$183.3M -$8.250M
YoY Change 2280.94% 2392.52%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $135.0M $150.5M -$8.249M
YoY Change
Total Liabilities & Shareholders Equity $148.3M $161.7M $207.9M
YoY Change -28.67% -22.35%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q3
OPERATING ACTIVITIES
Net Income -$13.17M -$23.16M -$897.8K
YoY Change 1367.11% 58.84%
Depreciation, Depletion And Amortization $238.0K $263.0K $172.0K
YoY Change 38.37% 115.57%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Entity Central Index Key
EntityCentralIndexKey
0001833769
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39949
dei Entity Registrant Name
EntityRegistrantName
Hyperfine, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1569027
dei Entity Address Address Line1
EntityAddressAddressLine1
351 New Whitfield Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Guilford
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06437
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
-6767
dei Security12b Title
Security12bTitle
Class A common stock, $0.0001 Par Value Per Share
dei Trading Symbol
TradingSymbol
HYPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132482000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188498000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1259000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2662000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
296000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
32000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2702000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
553000
CY2022Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1475000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
91000
CY2022Q3 us-gaap Inventory Net
InventoryNet
4002000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4310000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1796000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1357000
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
14000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
143716000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
197485000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3448000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3753000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196425000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136320000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
134983000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1167000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1235000
CY2022Q3 us-gaap Liabilities
Liabilities
13348000
CY2022Q3 us-gaap Assets
Assets
148331000
CY2021Q4 us-gaap Liabilities
Liabilities
16246000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
331401000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
322540000
CY2021Q4 us-gaap Assets
Assets
202473000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
741000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2248000
CY2022Q3 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1259000
CY2021Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
2662000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1449000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
730000
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
61000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1981000
CY2022Q3 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8949000
CY2021Q4 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8115000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12459000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15736000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
889000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
510000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186227000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148331000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
202473000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2348000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
371000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5390000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1060000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1660000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
709000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4783000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1774000
CY2022Q3 us-gaap Gross Profit
GrossProfit
688000
CY2021Q3 us-gaap Gross Profit
GrossProfit
-338000
us-gaap Gross Profit
GrossProfit
607000
us-gaap Gross Profit
GrossProfit
-714000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7338000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6438000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22937000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16949000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3198000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6827000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26570000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15348000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3434000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2787000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
150508000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13171000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
827000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13171000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16392000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60105000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38766000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11345000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5770000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13970000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
16052000
us-gaap Operating Expenses
OperatingExpenses
60852000
us-gaap Operating Expenses
OperatingExpenses
38067000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13282000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16390000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60245000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38781000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
170000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Investment Income Interest
InvestmentIncomeInterest
203000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13171000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16392000
us-gaap Net Income Loss
NetIncomeLoss
-60105000
us-gaap Net Income Loss
NetIncomeLoss
-38766000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.66
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-22.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-22.56
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70509639
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70509639
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1892208
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1892208
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70398103
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70398103
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1718489
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1718489
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186227000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23775000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4111000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166563000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23159000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7102000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-2354000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
134983000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-61054000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7794000
CY2021Q1 hypr Adjustments To Additional Paid In Capital Investments
AdjustmentsToAdditionalPaidInCapitalInvestments
700000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
267000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-67832000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-14580000
CY2021Q2 hypr Adjustments To Additional Paid In Capital Investments
AdjustmentsToAdditionalPaidInCapitalInvestments
2816000
CY2021Q2 hypr Conversion Of Liminal Common Stock
ConversionOfLiminalCommonStock
-9350000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
149000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1489000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-87308000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16392000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1264000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1375000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-101061000
us-gaap Profit Loss
ProfitLoss
-60105000
us-gaap Profit Loss
ProfitLoss
-38766000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
754000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
389000
us-gaap Share Based Compensation
ShareBasedCompensation
8859000
us-gaap Share Based Compensation
ShareBasedCompensation
3131000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
19000
us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
6000
us-gaap Net Investment In Lease Purchase
NetInvestmentInLeasePurchase
7000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2149000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
766000
hypr Unbilled Receivables
UnbilledReceivables
1384000
hypr Unbilled Receivables
UnbilledReceivables
48000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-308000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1064000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
439000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2909000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-14000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-1452000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
-158000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-62000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
614000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1522000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3923000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-1403000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1857000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1098000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
956000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1920000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4656000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
191160000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64286000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1198000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133741000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68942000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132482000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2030000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56994000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65475000
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
3516000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35439000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-57419000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29047000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
427000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1736000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-427000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1736000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1462000
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
30468000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
7000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1259000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3467000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133741000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68942000
hypr Cash Received From Exchange Of Research And Development Tax Credits
CashReceivedFromExchangeOfResearchAndDevelopmentTaxCredits
324000
hypr Write Off Of Notes Receivable
WriteOffOfNotesReceivable
90000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed combined and consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts reported in its condensed combined and consolidated financial statements and accompanying notes. Future events and their effects</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cannot be determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions included:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue recognition, including determination of the timing and pattern of satisfaction of performance obligations, determination of the standalone selling price (“SSP”) of performance obligations and estimation of variable consideration;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Allowance for doubtful accounts;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net realizable value (the selling price as well as estimated costs of disposal and transportation) of inventory, and demand and future use of inventory;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowances with respect to deferred tax assets; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assumptions underlying the fair value used in the calculation of stock-based compensation expense.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s condensed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">combined and consolidated financial statements. </span>
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2348000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
371000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5390000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1060000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2702000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
553000
CY2022Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1475000
CY2021Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
91000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1449000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
730000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
889000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
510000
hypr Revenue Recognize Receivable Payment Terms Range Minimum
RevenueRecognizeReceivablePaymentTermsRangeMinimum
P20D
hypr Revenue Recognize Receivable Payment Terms Range Maximum
RevenueRecognizeReceivablePaymentTermsRangeMaximum
P6M
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1636000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1955000
CY2022Q3 us-gaap Inventory Net
InventoryNet
4002000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4310000
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
118000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
501000
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
43000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
157000
CY2022Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
251000
CY2021Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
158000
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
5101000
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2800000
CY2022Q3 hypr Revenue Remaining Performance Obligation Expected Timing Percentage
RevenueRemainingPerformanceObligationExpectedTimingPercentage
0.09
CY2022Q3 hypr Revenue Remaining Performance Obligation Expected Timing Percentage
RevenueRemainingPerformanceObligationExpectedTimingPercentage
0.91
hypr Fair Value Assets Transfer Between Levels Amount
FairValueAssetsTransferBetweenLevelsAmount
0
CY2022Q3 hypr Fair Value Assets Transfer Between Levels Amount
FairValueAssetsTransferBetweenLevelsAmount
0
hypr Fair Value Assets Transfer Between Levels Amount
FairValueAssetsTransferBetweenLevelsAmount
0
CY2021Q3 hypr Fair Value Assets Transfer Between Levels Amount
FairValueAssetsTransferBetweenLevelsAmount
0
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2366000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2355000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5591000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
431000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
452000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2896000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
441000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5163000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2143000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1410000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3448000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3753000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
238000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
754000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
172000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
389000
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3536000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3421000
CY2022Q3 hypr Accrued Contracted Services Current
AccruedContractedServicesCurrent
1891000
CY2021Q4 hypr Accrued Contracted Services Current
AccruedContractedServicesCurrent
2711000
CY2021Q4 hypr Accrued Bonus And Other Costs Current
AccruedBonusAndOtherCostsCurrent
1071000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
195000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19000
CY2022Q3 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8949000
CY2021Q4 hypr Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8115000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7522136
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4231693
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
271368
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11482461
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
699170
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16375
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
383090
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11782166
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
122800
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3360486
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8544480
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
4501000
CY2022Q3 hypr Option Repricing Approved Date
OptionRepricingApprovedDate
2022-08-24
CY2022Q3 hypr Option Repricing Effected Date
OptionRepricingEffectedDate
2022-10-31
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-2354000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1375000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8859000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3131000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13171000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16392000
us-gaap Net Income Loss
NetIncomeLoss
-60105000
us-gaap Net Income Loss
NetIncomeLoss
-38766000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13171000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16392000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60105000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38766000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70509639
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70509639
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1892208
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1892208
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70398103
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70398103
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1718489
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1718489
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.66
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-22.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-22.56
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20032859
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53681288
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20032859
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53681288
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q1 us-gaap Due From Employees Noncurrent
DueFromEmployeesNoncurrent
90000
CY2018Q1 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.0168
CY2022Q1 hypr Due From Employees Forgiveness
DueFromEmployeesForgiveness
90000
CY2020Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1610000
CY2020 hypr Number Of Sites
NumberOfSites
20
CY2021 hypr Grant Awarded
GrantAwarded
3300000
CY2021 hypr Grant Awarded For Provision And Equipping
GrantAwardedForProvisionAndEquipping
2500000
CY2021 hypr Number Of Sites
NumberOfSites
5
hypr Grant Awarded For Provision And Equipping
GrantAwardedForProvisionAndEquipping
800000
CY2022Q3 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
1259000
CY2021Q4 hypr Deferred Grant Funding Current
DeferredGrantFundingCurrent
2662000
CY2022Q3 hypr Grant Fund Required To Return Under Provisions
GrantFundRequiredToReturnUnderProvisions
0
CY2021Q4 hypr Grant Fund Required To Return Under Provisions
GrantFundRequiredToReturnUnderProvisions
0
CY2021 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1000000
CY2022Q3 hypr Earn Out Liability
EarnOutLiability
0

Files In Submission

Name View Source Status
0000950170-22-024488-index-headers.html Edgar Link pending
0000950170-22-024488-index.html Edgar Link pending
0000950170-22-024488.txt Edgar Link pending
0000950170-22-024488-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hypr-20220930.htm Edgar Link pending
hypr-20220930.xsd Edgar Link pending
hypr-ex10_3.htm Edgar Link pending
hypr-ex31_1.htm Edgar Link pending
hypr-ex31_2.htm Edgar Link pending
hypr-ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hypr-20220930_cal.xml Edgar Link unprocessable
hypr-20220930_def.xml Edgar Link unprocessable
hypr-20220930_lab.xml Edgar Link unprocessable
hypr-20220930_pre.xml Edgar Link unprocessable
hypr-20220930_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending